Research programme: PAR-1 antagonists - Pierre Fabre
Alternative Names: F 16618Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Pierre Fabre
- Class Small molecules
- Mechanism of Action PAR 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arterial thrombosis; Coronary artery restenosis; Vascular injuries
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Arterial-thrombosis in France
- 16 Jul 2016 No recent reports of development identified for preclinical development in Coronary-artery-restenosis in France
- 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular injuries in France